Compare iShares Bitcoin Trust (IBIT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs GeneDx Holdings Corp — how do they compare? iShares Bitcoin Trust trades at $46.71 (market cap $67.31B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: iShares Bitcoin Trust is far larger — about 33.3× GeneDx Holdings Corp's market cap, and iShares Bitcoin Trust is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and GeneDx Holdings Corp for 19 Days on average.
| IBIT | WGS | |
|---|---|---|
Market Cap | $67.31B | $2.02B |
Volume | 56,154,544 | 734,640 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $167.51 |
52-Week Low | $33.29 | $34.51 |
Typical Hold Time | 40 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $46.79, down 0.89% with bearish technical signals from oscillators and mixed moving averages. Recent news highlights significant institutional inflows, including a $196 million single-day inflow on October 1, 2026. The stock faces resistance at $47-$48 with support at $44-$46, while RSI levels suggest potential oversold conditions. Financial ratios remain undisclosed in current data.
Outlook hinges on sustained institutional interest amid volatile ETF flows, with Q3 inflows reversing prior outflows. Risks include fee structures impacting returns and market sentiment shifts. Upside potential exists if Bitcoin ETF momentum continues, but investors face exposure to crypto market volatility without direct cash flow benefits.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
